Alzheimer’s Disease – Current Treatment – Current Treatment: Physician Insights – Alzheimer’s Disease (US)
Alzheimer’s disease (AD) affects cognition and causes neuropsychiatric symptoms (e.g., agitation, aggression, psychosis) that intensify as the disease advances. Disease-modifying therapy (DMT) is now a reality in AD with the availability of Eisai / Biogen’s Leqembi / Leqembi Iqlik (lecanemab) and Eli Lilly’s Kisunla (donanemab). These agents are vying for uptake and beginning to unlock the potential of a DMT as the U.S. healthcare system adapts to identify AD patients earlier in the disease course. Lundbeck / Otsuka’s Rexulti (brexpiprazole) is the first drug FDA-approved for AD agitation, and the late-phase pipeline holds numerous additional competitors. This report will provide developers of new and emerging DMTs and neuropsychiatric treatments for AD with insights into the patient characteristics driving or constraining eligibility for novel options. It will also delve into diagnosis and treatment initiation in AD, as well as neurologists’ and PCPs’ prescribing practices and rationale. prescribing practices and rationale.
Questions answered
- What factors are driving the selection between Leqembi and Kisunla? What are key drivers and constrainers of their use?
- What percentage of AD patients have comorbid behavioral conditions? What do neurologists prescribe to treat these symptoms?
- How have neurologists’ and PCPs’ prescribing changed in the past year? What changes are they anticipating in the coming year?
- How do PCPs and neurologists differ in their prescribing practices?
- What types of assessments are physicians completing at follow-up appointments after initiating Leqembi?
- Which biomarker tests are clinicians using, and how?
- What percentage of AD patients are on antipsychotics, and what is the patient share of individual therapies?
Product description
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
Markets covered: United States
Primary research: Survey of 70 U.S. neurologists and 30 U.S. PCPs
Key drugs covered: Leqembi / Leqembi Iqlik, Kisunla, Rexulti, donepezil, galantamine, memantine, Namzaric, rivastigmine, atypical antipsychotics, antidepressants
Key companies: Eisai / Biogen, Otsuka / Lundbeck, AbbVie, Eli Lilly
Key insights provided:
- Factors influencing disease management and treatment decisions.
- Drivers and constraints of treatment selection.
- Physician-reported treatment practices and brand-level patient shares.
- Rationale for changes in treatment approach.
- Physician insight on persistency and compliance.
- Physician-reported recent/anticipated changes in brand usage or treatment approach.
